Health

Tech Leaders and Scientists Call for Global Rules on Synthetic DNA Safety as Biosecurity Risks Grow

Published

1 hour ago

June 5, 2026

Senior executives from leading artificial intelligence and technology firms, including OpenAI, Anthropic, Microsoft AI and Google DeepMind, have joined biotechnology researchers in calling for stricter government oversight of synthetic DNA purchases in the United States. In a joint appeal to Congress, the group urged mandatory safety screening and tracking systems for DNA orders, warning that rapid advances in AI and biotechnology are lowering barriers to misuse.

Synthetic DNA is artificially produced genetic material that can be ordered from commercial suppliers and delivered to laboratories. It is widely used in vaccine development, medical research, drug discovery and industrial biotechnology. However, experts warn that the same technology could also be misused to design harmful pathogens.

The letter emphasised that online access to synthetic DNA has already transformed science by enabling faster research and lowering costs for smaller laboratories. At the same time, it warned that the ability to synthesise genetic sequences raises the theoretical risk that individuals with malicious intent could attempt to recreate dangerous biological agents.

While many DNA synthesis companies currently carry out voluntary customer screening, there is no uniform legal requirement to do so. The signatories are calling for mandatory checks, arguing that consistent screening is one of the most effective and least disruptive ways to reduce biosecurity risks. They also recommend introducing record-keeping systems that would allow suspicious activity to be traced, even when individual orders appear harmless on their own.

Experts involved in the initiative say the urgency is increasing due to advances in artificial intelligence. Modern AI systems are now capable of answering highly complex biological questions and, in some cases, performing at levels comparable to trained virologists. Researchers caution that this could gradually weaken traditional knowledge barriers that have helped limit access to sensitive biological capabilities.

The concerns extend beyond industry leaders. Earlier this year, scientists from institutions including Johns Hopkins University, the University of Oxford and Stanford University also warned that unrestricted access to certain biological datasets could increase the risk of misuse. They called for safeguards such as data watermarking, user verification systems and audit trails to monitor access to sensitive information.

In Europe, policymakers are also beginning to respond. The European Commission’s proposed EU Biotech Act, introduced in 2025, highlights rising biosecurity concerns linked to the wider availability of biotechnology tools. The draft framework identifies synthetic nucleic acid sequences as high-risk materials and suggests new rules including customer verification and reporting of suspicious orders.

Despite these developments, no comprehensive global standard currently exists for regulating synthetic DNA procurement. Experts argue that fragmented national approaches may leave gaps in oversight, making coordinated international action increasingly important as both AI and biotechnology continue to advance.

Health

Saudi Arabia and Mayo Clinic Partner to Develop AI Model for Healthcare

Published

22 hours ago

June 4, 2026

Web Reporter

Microsoft and the Mayo Clinic have announced a partnership to develop a new artificial intelligence model tailored specifically for healthcare, combining advanced technology with clinical expertise to improve patient care and support medical professionals.

The initiative brings together Mayo Clinic’s extensive medical knowledge, anonymized patient data and experience in healthcare delivery with Microsoft’s artificial intelligence, cloud computing and engineering capabilities. The organizations said the model is intended to assist with analyzing complex clinical information, supporting earlier diagnoses and helping clinicians create more personalized treatment plans.

The collaboration marks a significant step in the growing use of AI in healthcare, an area that many experts believe has the potential to transform medical services by improving efficiency and expanding access to specialized knowledge.

Dr. Gianrico Farrugia, president and chief executive officer of Mayo Clinic, said the institution has long viewed artificial intelligence as a tool capable of advancing healthcare innovation. He noted that Mayo Clinic launched its data-focused Mayo Clinic Platform seven years ago to create a secure foundation for research and technological development using de-identified patient information.

Farrugia said the new partnership with Microsoft aims to extend Mayo Clinic’s expertise to a broader patient population while accelerating medical innovation.

Under the agreement, the AI model will be owned by Mayo Clinic. Microsoft plans to make the technology available through Azure Foundry application programming interfaces, allowing developers and healthcare organizations to connect the model to their own applications and services.

The organizations said the model is initially being deployed within Mayo Clinic’s clinical environment, where it will undergo testing and refinement through real-world use. Details regarding the scale of deployment, specific medical specialties involved and a timeline for broader availability have not yet been disclosed.

Healthcare has emerged as one of the most active sectors for AI development, though it presents unique challenges. Medical AI systems must process complex patient information, account for medical histories and meet strict standards for safety, privacy and reliability.

Mustafa Suleyman, chief executive of Microsoft AI, described the collaboration as an important step toward what he called “frontier medical intelligence.” He said Mayo Clinic’s clinical expertise and extensive health data resources make it an ideal partner for developing advanced healthcare-focused AI models.

The announcement comes as the use of AI in health-related decision-making continues to grow among consumers. Surveys have shown increasing numbers of people turning to AI-powered tools for medical information and guidance.

At the same time, regulators and healthcare professionals have emphasized the need for safeguards to address concerns about accuracy, bias, privacy and accountability. Under the European Union’s AI Act, medical AI systems are classified as high-risk technologies and must meet strict requirements, including risk management measures, quality data standards, transparency and human oversight.

The Microsoft-Mayo Clinic partnership reflects the growing effort to balance technological innovation with patient safety as AI becomes more deeply integrated into healthcare systems worldwide.

Health

Study Suggests Weight-Loss Drugs May Reduce Breast Cancer Risk in Women

Published

23 hours ago

June 4, 2026

Web Reporter

Women taking popular weight-loss medications such as Ozempic and Mounjaro may face a significantly lower risk of developing breast cancer, according to new research presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting.

The study, which analyzed data from more than 110,000 women between the ages of 45 and 80, found that users of glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 drugs, were about 30 percent less likely to develop breast cancer than women who did not take the medications.

Researchers said the reduction in risk remained consistent regardless of age, race, ethnicity, body mass index, breast density or diabetes status.

The findings add to growing scientific interest in the potential health benefits of GLP-1 medications beyond weight management and blood sugar control. These drugs, originally developed to treat type 2 diabetes, work by mimicking naturally occurring hormones that help regulate appetite, insulin production and glucose levels. Their effectiveness in promoting weight loss has led to widespread use in recent years.

Elizabeth McDonald, a professor of radiology at the University of Pennsylvania Perelman School of Medicine and a breast radiologist involved in the research, said the medications are attracting attention in cancer research because they influence multiple biological pathways linked to cancer development.

Researchers noted that obesity is a well-established risk factor for breast cancer and that weight reduction has long been associated with lower cancer risk. However, they believe the benefits of GLP-1 medications may extend beyond weight loss alone.

Evidence suggests the drugs may help reduce systemic inflammation, a condition increasingly linked to cancer development. Chronic inflammation can create an environment that allows cancer cells to grow, survive and spread more easily. Since inflammation plays a significant role in breast cancer progression, scientists are exploring whether these medications could offer additional protective effects.

Despite the promising findings, researchers cautioned that the study was observational and does not prove that GLP-1 medications directly prevent breast cancer. They also noted that the research focused exclusively on women with overweight or obesity, meaning the results may not apply to women in other weight categories.

Another factor highlighted by the study is that people taking GLP-1 medications often have more frequent medical appointments, which can increase opportunities for cancer screening and diagnosis.

The researchers said the findings justify further investigation through randomized clinical trials. They proposed future studies examining whether GLP-1 drugs could simultaneously help prevent cancer, cardiovascular disease and metabolic changes associated with menopause.

Additional research presented at the ASCO meeting pointed to similar benefits. An Italian study reported that women with advanced hormone receptor-positive breast cancer who used GLP-1 medications survived nearly 19 months longer on average than patients who did not receive the drugs.

Scientists say the emerging evidence underscores the need for further research into the broader health impacts of GLP-1 therapies.

Health

WHO Reports Sharp Revision in Congo Ebola Cases as Vaccine Efforts Accelerate

Published

2 days ago

June 3, 2026

Web Reporter

The World Health Organization has significantly revised down its estimate of suspected Ebola cases in the Democratic Republic of Congo, easing earlier fears that the outbreak was far larger than initially believed.

As of 31 May, there are 116 suspected cases and 321 confirmed infections linked to the ongoing outbreak in the country, down from earlier estimates that suggested more than 1,000 suspected cases. The updated figures were confirmed on Tuesday by WHO spokesperson Christian Lindmeier during a briefing in Geneva.

The revision reflects the results of expanded laboratory testing, which ruled out a large number of initially suspected patients. According to the WHO, many of those cases were found to involve other illnesses or mild fever-related conditions unrelated to Ebola.

“They either have other diseases or have just had a fever and nothing else,” Lindmeier said, explaining the sharp decline in suspected infections.

Despite the reassessment, the outbreak remains serious. The WHO has confirmed 48 deaths and several recoveries, while neighbouring Uganda has recorded nine cases and one death connected to the same outbreak.

The strain involved is a less common variant of the Ebola virus, complicating response efforts due to the absence of widely available targeted vaccines or treatments. Health authorities in Congo say containment has been hindered by limited early detection capacity, difficulties in isolating patients quickly, and challenges in conducting effective contact tracing in remote regions.

Safe burial practices and improved infection control in health facilities remain key priorities, the country’s health ministry said, as teams work to limit further spread in affected areas.

During a visit to Bunia in eastern Congo, the epicentre of the outbreak, WHO Director-General Tedros Adhanom Ghebreyesus confirmed that five patients have now recovered from the disease. Four were discharged on the day of his visit, while another was released shortly before.

“We’re still working on vaccines and treatments, but that doesn’t mean that people cannot recover from Ebola,” Tedros said while inaugurating a new treatment centre in the city.

Global health agencies are also stepping up efforts to accelerate vaccine development. The Coalition for Epidemic Preparedness Innovations (CEPI) announced plans to fast-track three experimental vaccines targeting the Bundibugyo strain of Ebola, which is responsible for the current outbreak.

CEPI said it will invest up to €53 million to support vaccine candidates being developed by the International AIDS Vaccine Initiative, Moderna, and the University of Oxford, with manufacturing support from the Serum Institute of India.

The WHO has identified these candidates as the most promising in development, as researchers race to strengthen the global response to a virus that continues to challenge health systems in fragile and conflict-affected regions.

For now, authorities stress that containment depends on rapid diagnosis, strict infection control, and coordinated international support as the outbreak continues to evolve.